Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Advances on Greener Asymmetric Synthesis of Antiviral Drugs via Organocatalysis

Version 1 : Received: 11 October 2021 / Approved: 14 October 2021 / Online: 14 October 2021 (11:05:51 CEST)

A peer-reviewed article of this Preprint also exists.

da Silva, E.M.; Vidal, H.D.A.; Corrêa, A.G. Advances on Greener Asymmetric Synthesis of Antiviral Drugs via Organocatalysis. Pharmaceuticals 2021, 14, 1125. da Silva, E.M.; Vidal, H.D.A.; Corrêa, A.G. Advances on Greener Asymmetric Synthesis of Antiviral Drugs via Organocatalysis. Pharmaceuticals 2021, 14, 1125.

Journal reference: Pharmaceuticals 2021, 14, 1125
DOI: 10.3390/ph14111125

Abstract

Viral infections inflict many serious human diseases, being responsible for remarkably high mortality rates. In this sense, both the academy and the pharmaceutical industry are continuously searching for new compounds with antiviral activity, and in addition, face the challenge of developing greener and more efficient methods to synthesize these compounds. This becomes even more important with drugs possessing stereogenic centers as highly enantioselective processes are required. In this minireview, the advances achieved to improve synthetic routes efficiency and sustainability of important commercially antiviral chiral drugs are discussed, highlighting the use of organocatalytic methods.

Keywords

antivirals; green chemistry; selectivity; asymmetric synthesis; organocatalysis

Subject

CHEMISTRY, Organic Chemistry

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.